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The effects of various local anaesthetics (LAS) on ryanodine binding of the sheep brain ryanodine receptor were tested. Tetracaine and dtbucame 
inhibit the binding with half-maximal mhibttton (CI,,) of 0.12 mM and 0.7 mM, respectively Ltdocaine and Its analog QX-314. on the other hand, 
stimulate the binding up to 3-fold with half-maximal stimulation occurrmg wtth about 2 mM of the drugs. Lidocame increases both the receptor 
affinity for ryanodine by about 5-fold and the rate of ryanodine association wtth its bmdmg site by about 6-fold Tetracaine and lidocaine also 
interact with the purified brain ryanodme receptor and produce inhibitory and stimulatory effects stmtlar to those obtained with the membrane- 
bound receptor. The interaction of the LAS with the brain ryanodine receptor. as well as with the skeletal muscle receptor [J Memb. Biol. 133 
(1993) 171-1821. suggest that ryanodine receptor possesses mtrmstc bindmg site(s) for LAS. 
Local anaesthetic, Ryanodine receptor; Brain microsome; Ca” release channel 
1. INTRODUCTION and channel activities are affected by various modula- 
tors such as ATP and Ca” [13,15,18,19]. 
It is accepted that the primary mode of membrane 
conduction blockade by local anaesthetics (LAS) occurs 
through the inhibition of voltage-gated sodium chan- 
nels [l]. However, other voltage-gated channels [l-3] 
and ligand-gated channels [4..5] are also sensitive to 
local anaesthetics. 
In this study we demonstrate the interaction of sev- 
era1 local anaesthetics with the membrane-bound and 
purified brain-ryanodine receptor. 
2. MATERIALS AND METHODS 
Local anaesthetics also have diverse effects on other 
cell activities such as Ca’+ transport across the sarco- 
plasmic reticulum [6-Q, inositol phospholipid hydroly- 
sis [9]. protein kinase C activity [lo], and on the binding 
of the neutral alkaloid ryanodine by the skeletal [l l] or 
the hepatic [12] receptors. 
Recently [13-181 the presence of ryanodine binding 
protein in brain microsomes was demonstrated. The 
brain ryanodine receptor shares many of the character- 
istics of the muscle receptor: (a) possesses high- and 
low-affinity ryanodine binding sites [13.15.18]; (b) the 
protein exists as a tetrameric complex of about 420 kDa 
subunits [15,18]; (c) its incorporation into planar lipid 
bilayers results in the appearance of ryanodine-sensitive 
Ca2’ channels [13,18]: (d) both the ryanodine binding 
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Abbreviations. EGTA. ethylene glycol bis-@-aminoethyl ether)- 
N.N,N’,N’-tetraacetic acid; Tricine, N-[2-hydroxy-l.l-bts-(thyrox- 
ymethyl)-ethyl]-glycine; MOPS, 3-(N-morpholino)-propensulfonic 
acid: LAS, local anaesthetics. 
2.1. Muterial.7 
ATP. EGTA, Tris, Trtcine. MOPS, caffeine. tetracaine, dtbucaine, 
and lidocame were obtained from Sigma. and QX-314 was obtamed 
from Alomone Labs. Jerusalem. [ZH]Ryanodme was purchased from 
New England Nuclear, and unlabelled ryanodine was obtained from 
Calbtochem. Dibucaine and lidocame were prepared m ethanol and 
then diluted to 25% ethanol whtle stnrmg, and the pH was adjusted 
to about 7.0. The final ethanol concentration in control and LAs- 
contaming samples never exceeded 2%. 
2.2. Metnbrune preparution 
Mtcrosomal membranes were prepared from whole sheep brain 
essenttally as described previously [20]. The brain was homogemzed 
m Ice-cold buffer A (0.32 M sucrose, 5 mM NaH,PO,. pH 7.4.0.3 mM 
PMSF. 0.8 mM benzamtdine. 0.5,@ml leupeptin and 0.5 pug/ml apro- 
tenme) (8 ml per g wet weight) with 10 strokes of a motor-driven 
teflonglass homogenizer. Homogenate was centrifuged for IO min at 
1,000 x g. The supernatant was retained, and the pellet was homoge- 
nized and centrifuged as before. The supernatants were combined and 
re-centrifuged for 60 min at 17.000 x g. The pellets were resuspended 
m buffer A (approxtmately 2.5 ml per g wet weight of brain) with a 
tight-fitting homogemzer. This material (6 ml) was layered on sucrose 
gradients of 7.5 ml each of 1.2. 1.0 and 0.8 M sucrose (containing 5 
mM NaH,PO, pH 7.4 and the protease mhibttors). centrifuged for 90 
min at 100.000 x g (Beckman SW’27). The membranes within the 1 M 
sucrose and at the 1.0-l .2 M sucrose Interface were collected, diluted 
slowly with 3 ~01s. of 5 mM NaH?PO,. pH 7.4 and pelleted at 
100,000 x g for 45 min. The pellets were resuspended in buffer A 
(without antiproteases), frozen in liquid nitrogen, and stored at 
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Fig. 1. Effects of tetracame and dibucaine on ryanodme binding to brain microsomes. Brain mlcrosomal membranes (2.5 mg/ml) were assayed for 
ryanodine bmdmg m 0.5 M (0) or 1 M (0) of NaCl m the absence and in the presence of the indicated LAS as described m sectlon 2. Control activities 
( 100%) were: 35 and 84 fmol ryanodme bound/mg protein m the presence of 0 5 M NaCl and 1 M NaCI. respectively. 
-70°C JunctIonal SR membranes were prepared from rabbit fast 
twitch skeletal muscle as described by Saito et al [21]. 
2 3. [3HjRyanodme bmding 
Unless otherwise specified, 350 pg of brain microsomal membranes 
in 100,ul of a standard bmdmg solution contammg 0.5 M or 1 M NaCl. 
20 mM MOPS, pH 7.4 and 50 PM CaCl, were mcubated for I --3 h at 
37°C with 5 to 20 nM [‘Hlryanodme Unbound ryanodme was sepa- 
rated from protein-bound ryanodine by filtration of the samples 
through Whatman GF/C filters. followed by washmg three times with 
5 ml of ice-cold buffer contaming 0 2 M NaCl. 5 mM MOPS, pH 7 4 
and 50pM CaCIZ. The filters were dried, and the retained radioactivity 
was determined by standard liqmd scmtlllation counting techmques. 
Specific binding of [“Hlryanodme IS defined as the difference between 
the bindmg m the absence and in the presence of 100 PM unlabelled 
ryanodine 
3. RESULTS 
The effects of various concentrations of tetracaine 
and dibucaine on ryanodine binding by brain micro- 
somal membranes are illustrated in Fig. 1. Tetracaine 
and dibucaine inhibited ryanodine binding with half- 
maximal inhibition (Cl,,) occurring at about 0.12 mM 
and 0.7 mM for tetracaine and dibucaine, respectively. 
Dibucaine altered ryanodine binding in a biphasic man- 
ner; slight stimulation at low concentrations (< 300 PM) 
to the effects of dibucaine on the skeletal muscle ryan- 
odine receptor [l 11. Ryanodine binding by the skeletal, 
cardiac and brain ryanodine receptor is strongly en- 
hanced by increasing the ionic strength. Fig. 1 also 
shows that the degree of inhibition of ryanodine binding 
by tetracaine and dibucaine is dependent on the NaCl 
concentration present in the ryanodine binding me- 
dium. Increasing NaCl concentration from 0.5 M to 1 
M decreases the inhibition by 0.5 mM of tetracaine 
from 81% to 65% (Fig. 1A). For dibucaine. however. 
increasing NaCl from 0.5 to 1 M prevented the inhibi- 
tion of ryanodine binding by dibucaine (Fig. 1 B). 
The local anaesthetic lidocaine and its analog QX- 
314, on the other hand, stimulated the binding of ryan- 
odine up to ‘-fold (Fig. 2). However, the stimulation of 
ryanodine binding by QX-314 or lidocaine is decreased 
with increasing NaCl concentration, from stimulation 
of about 2-fold at 0.5 M NaCl to no stimulation in the 
presence of 1 .O M NaCl. This effect of NaCl is expected, 
since in the presence of 1 M NaCl ryanodine binding is 
close to its maximal level. The results in Figs. 1 and 2 
suggest that the site of LA interaction is either influ- 
enced directly by ionic strength or indirectly due to 
NaCl stabilization of a protein conformation with a 
and inhibition at higher concentrations. This is similar modified LA binding site. 
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Fig. 2. Effects of lidocame and QX-314 on ryanodine bindmg to the brain mlcrosomes. ExperImental condltlons for ryanodine bmdmg were as 
m Fig I. (‘2) and (0) indicate the presence of 0.5 M NaCl or I M NaCI. respectively. 
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Fig. 3. The influence of lidocaine on the affinity of the ryanodme binding site. [‘H]Ryanodine was assayed as m Fig. 1 in the presence of 0.5 M 
NaCl in the absence (e) and in the presence (0) of 6 mM lidocaine, except that the [‘Hlryanodine concentration was vaned. Saturation isotherms 
are shown in A and Scatchard plots in B. The calculated B,,, values were: 190 and 185 fmol/mg protem, and Kd of 61 nM and 13.7 nM m the 
absence and in the presence of lidocame, respectively. 
Fig. 3 shows the binding of ryanodine as a function 
of its concentration in the absence and in the presence 
of lidocaine. Scatchard plots analysis of ryanodine 
binding in the absence and in the presence of 6 mM 
Iidocaine indicates that lidocaine increased the apparent 
binding affinity (I&) about 4.4-fold from 61 to 13.7 nM. 
In contrast, similar B,,, values were obtained with 0.5 
M NaCl k 6 mM lidocaine (&,, = 190 and 184 fmol/ 
mg protein). Thus the stimulation of ryanodine binding 
produced by lidocaine (at low NaCl concentration) is 
attributable to increased receptor affinity for the ligand. 
Scatchard plot analysis of ryanodine binding in the 
absence and in the presence of 0.4 mM tetracaine indi- 
cates that tetracaine decreases the maximum binding 
sites (B,,,) from 204 fmol/mg of protein to 114 fmol/mg 
of protein (n = 3) with no modification of the apparent 
binding affinity (I&) (results not shown). 
The effect of lidocaine on the ryanodine association 
with, and dissociation from, its binding site are shown 
in Fig. 4. Lidocaine increased ryanodine binding by 3- 
80 
A Lidocaine 0 
to 4-fold during the period of time tested (5 to 120 min, 
Fig. 4A, inset). Kinetic analysis of the data (Fig. 4A) 
indicates that lidocaine increased the observed associa- 
tion rate constant (Kobs). Ryanodine associates with its 
binding site with KObS of 0.021 k 0.0075 (n = 2) and 
0.0521 ? 0.0013 (n = 2) min-’ in the absence and in the 
presence of lidocaine, respectively. The calculated 
pseudo-first-order association rate constants (K,) ob- 
tained in the absence and in the presence of lidocaine 
were: 2.57 x 10m4 k 0.29 x 10W4 (n = 2) and 13.11 x 
10m4 k 0.74 k 10m4 (n = 2) M-’ . min-’ for the control 
and for lidocaine, respectively. Dissociation of bound 
ryanodine at equilibrium was initiated by SO-fold dilu- 
tion (Fig. 4B). A similar monophasic dissociation was 
obtained in the absence and in the presence of 6 mM 
lidocaine (K-, = 0.0147 min-‘). The I& calculated from 
association and dissociation constants are 64 and 11.7 
nM in the absence and in the presence of lidocaine, 
respectively, which are close to the Kd calculated from 
saturation experiments (Fig. 3). 
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Fig. 4. Effect of lidocame on equihbrium bmdmg of [3H]ryanodine and dlssoclatlon kinetics. In A. the membranes (2.5 mg/ml) were incubated with 
10 nM ryanodine at 37”C, as m Fig. 1, in the absence (0) and in the presence (0) of 6 mM lidocame. After the indicated incubation time, ahquots 
were assayed for bound ryanodine (Bt). The maximal amounts of ryanodine bound at the plateau (Be) were 32 and 66 fmol/mg protein, in the absence 
and m the presence of lidocaine, respectively. In B, the membranes were incubated with 10 nM ryanodine as in A. After 2 h, ahquots were assayed 
for bound ryanodine (Be = 33.0 fmol/mg protein). Dissociation of bound ryanodme was initiated by 80-fold dilution with the bmding medium 
(without ryanodme) with (0) and without (0) 6 mM hdocaine, and determination of the residual ryanodine bound at the indicated time (Bt). The 
calculated K-, was (0.0147) min-’ in the absence and in the presence of hdocaine. K, was calculated from the Kobs, as described previously 1241, 
using the followmg equation: Kobs = K,[L][R]/Be. where [L] = ryanodine concentration, [R] = ryanodine receptor = B,,,,, (190 fmol/mg protein), 
K, = 2.28 x 10e4 and 12.37 x 10m4 M-’ min-’ in the absence and in the presence of lidocaine, respectively. 
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The effects of different modulators of ryanodine 
binding to their receptor on the inhibition of the ryan- 
odine binding by tetracaine are shown in Table I. ATP 
and caffeine, as shown previously [ 13,161 stimulated the 
binding of ryanodine to its receptor. The inhibition of 
ryanodine binding by tetracaine was not affected by 
caffeine, but it increased in the presence of ATP (Table 
I ). The binding of ryanodine is absolutely dependent on 
PM concentrations of Ca” [16]. Ca” at the indicated 
concentrations has no significant effect on ryanodine 
binding, but it increases the binding inhibition by tetra- 
Caine from 70% to 100% (Table I). 
The effects of different LAS on ryanodine binding to 
the purified ryanodine receptor are shown in Table II. 
As with the membrane-bound receptor tetracaine and 
dibucaine inhibited the binding, and lidocaine stimu- 
lated the binding to the purified receptor at the same 
range of concentrations. Thus, the experiments in Table 
II indicate that the drugs tested interact directly with the 
ryanodine receptor and that their binding sites are pre- 
served in the purified receptor. 
4. DISCUSSION 
In this study, the effects of local anaesthetics on ryan- 
odine binding to the brain membrane-bound and puri- 
fied ryanodine receptor are presented. We found that 
dibucaine and tetracaine inhibited ryanodine binding to 
both membrane bound and purified ryanodine receptor. 
while lidocaine and QX-314 stimulated up to 3-fold 
ryanodine binding. These results indicate a specific in- 
teraction of LAS with the brain ryanodine receptor. The 
interaction of LAS with the purified ryanodine receptor 
suggests that the receptor possesses intrinsic binding site 
or sites for LAS. Similar results have been reported 
recently for the skeletal muscle ryanodine receptor [I 11. 
Based on a structure-activity relationship. we proposed 
a model for the LAS site of interaction in the skeletal 
muscle ryanodine receptor [l 11. Although in this study 
Table I 
Effect of ATP, Ca” and caffeme on the inhibition of ryanodine bind- 
mg by tetracaine 
Additions [ZH]Ryanodme bound 
(fmollmg protein) 
- Tetracaine + Tetracaine 
None 48.5 14 (70) 
ATP. 1 mM 69 0 
CaC&, 0.2 mM 41 0 
CaC12, 1 .O mM 54 0 
Caffeme, 10 mM 96 5 26 (73) 
Caffeine, 20 mM 99 30 (70) 
[ZH]Ryanodine binding was assayed as m Fig. 1 m the absence or in 
the presence of tetracaine (0.4 mM) and of the indicated compounds. 
Free Ca’+ concentration was 50pM m the absence and in the presence 
of ATP. The numbers in parentheses indtcate the % of inhibition. 
80 
Table II 
Comparison of the effects of local anaesthetics on ryanodme binding 
to the membrane-bound and the purified ryanodine receptor 
Additions Concentration 
(mM) 
[‘H]Ryanodme bound. 
% of control 
(fmol/mg protem) 
Membranes Purified 
None 35 7.974 
Tetracame 0.8 0 95 
Dtbucame 1.6 94 0 
Ltdocaine 3 39 10,399 
Lidocaine 6 60 13,065 
The bmdmg of [ZH]ryanodine (10 nM) to the brain microsomal mem- 
branes (2.5 mg/ml) and to the purified receptor (15.2 fig/ml) was 
determined as described m section 2. except that the assay temperature 
was 30°C. NaCl concentration was 0.5 M, and the indicated com- 
pounds were added to the assay medium. Brain ryanodme receptor 
was purified by the spermme-agarose method developed for the skel- 
etal muscle ryanodme receptor [23] and its ryanodine bindmg activity 
was assayed also. as descrtbed m [33]. 
we have used only four different LAS with inhibitory 
and stimulatory effects on ryanodine binding, the re- 
sults are very similar to those obtained with the skeletal 
muscle and, therefore, it is most probable that the na- 
ture of the LAS site of interaction is similar in both 
proteins. 
Tetracaine and QX-314 (and also procaine) have re- 
cently been applied to single channels incorporated into 
planar lipid bilayers [25]. Tetracaine (150 PM) halved 
channel open probability (cf our reported CI50 of 120 
,uM for ryanodine binding. [I l] and Fig. l), while QX- 
3 14 (which stimulated binding, [ 1 l] and Fig. 2) did not 
reduce channel open probability. 
The mechanism by which LAS exert their effects on 
nerves and muscles has been discussed extensively 
[1,6.22]. It is accepted. however, that there are specific 
interactions of LAS with Na’ channel [23,23], ace- 
tylcholine receptor [5], Ca’+ channels [2,3] and K’ chan- 
nels [3]. The findings that LAS modify the activities of 
various channels may suggest the presence of a common 
binding site for LAS in the different ionic channels. 
Since the brain ryanodine receptor is also a Ca’+ 
release channel [ 13.181, it is expected that, as with the 
SR membranes (see Table IV in ref. [l I]), LAS would 
affect its activity as a Ca’+ release channel. 
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